We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
ERK1/2 mitogen-activated protein kinase selectively mediates IL-13-induced lung inflammation and remodeling in vivo.
- Authors
Lee, Patty J.; Xuchen Zhang; Peiying Shan; Bing Ma; Chun Geun Lee; Homer, Robert J.; Zhou Zhu; Rincon, Mercedes; Mossman, Brooke T.; Elias, Jack A.; Zhang, Xuchen; Shan, Peiying; Ma, Bing; Lee, Chun Geun; Zhu, Zhou
- Abstract
IL-13 dysregulation plays a critical role in the pathogenesis of a variety of inflammatory and remodeling diseases. In these settings, STAT6 is believed to be the canonical signaling molecule mediating the tissue effects of IL-13. Signaling cascades involving MAPKs have been linked to inflammation and remodeling. We hypothesized that MAPKs play critical roles in effector responses induced by IL-13 in the lung. We found that Tg IL-13 expression in the lung led to potent activation of ERK1/2 but not JNK1/2 or p38. ERK1/2 activation also occurred in mice with null mutations of STAT6. Systemic administration of the MAPK/ERK kinase 1 (MEK1) inhibitor PD98059 or use of Tg mice in which a dominant-negative MEK1 construct was expressed inhibited IL-13-induced inflammation and alveolar remodeling. There were associated decreases in IL-13-induced chemokines (MIP-1alpha/CCL-3, MIP-1beta/CCL-4, MIP-2/CXCL-1, RANTES/CCL-5), MMP-2, -9, -12, and -14, and cathepsin B and increased levels of alpha1-antitrypsin. IL-13-induced tissue and molecular responses were noted that were equally and differentially dependent on ERK1/2 and STAT6 signaling. Thus, ERK1/2 is activated by IL-13 in the lung in a STAT6-independent manner where it contributes to IL-13-induced inflammation and remodeling and is required for optimal IL-13 stimulation of specific chemokines and proteases as well as the inhibition of specific antiproteases. ERK1/2 regulators may be useful in the treatment of IL-13-induced diseases and disorders.
- Subjects
MITOGENS; PROTEIN kinases; LUNG diseases; LABORATORY mice; PROTEOLYTIC enzymes; GENETIC mutation; ANIMAL experimentation; CARRIER proteins; CHEMOKINES; COMPARATIVE studies; INFLAMMATION; INTERLEUKINS; LUNGS; RESEARCH methodology; MEDICAL cooperation; MICE; RESEARCH; TRANSFERASES; EVALUATION research; MATRIX metalloproteinases
- Publication
Journal of Clinical Investigation, 2006, Vol 116, Issue 1, p163
- ISSN
0021-9738
- Publication type
journal article
- DOI
10.1172/JCI25711